Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 24;163(2):655–665. doi: 10.1093/toxsci/kfy058

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018. Published by Oxford University Press on behalf of the Society of Toxicology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — Overview of the compound panel tested in this study. A, Pie chart showing the classification of 123 compounds into 70 that have been associated with DILI events in the clinic (shades of red) and 53 that have not been reported to cause clinically apparent liver injury (green). B, Venn-diagram visualizing the reported DILI patterns for the 70 DILI positive compounds. C, Pie chart depicting the distribution of the 123 tested compounds across therapeutic areas. D, Therapeutic c_max serum concentrations of DILI positive and DILI negative medications are overall similar. E, Most drugs tested in this study are extensively metabolized by the liver. Overall, the DILI negative compounds show a slight tendency for less hepatic metabolism compared with DILI positive drugs.